Abbott Laboratories to Spin Off $8.5 Billion Nutrition Business

Abbott Laboratories announced on Wednesday that it intends to spin off its global nutrition business into an independent, publicly traded company by the end of 2027, according to a corporate press release. The sweeping structural shift will carve out a vast portfolio of household names—including Similac, Ensure, and Pedialyte—that currently generate approximately $8.5 billion in annual sales. The move effectively separates Abbott's consumer-facing food products from its core medical devices and diagnostics divisions, representing a significant strategic pivot for the 138-year-old healthcare conglomerate.

Sharpening Strategic Focus

Under the terms of the plan, the new standalone entity will assume control of 14 global manufacturing facilities and roughly 16,000 employees. Abbott's current Chairman and CEO, Robert B. Ford, framed the decision as a strategic maneuver meant to unlock the maximum potential of two distinct corporate cultures. "This separation will benefit both companies, setting each one up for maximum success in its respective market," Ford stated. Following the tax-free distribution of shares, Abbott will retain its higher-growth, innovation-driven portfolios, including medical devices, diagnostics, and established pharmaceuticals.

Leadership and Market Position

Daniel Salvadori, Abbott’s current group president of established pharmaceuticals and nutritional products, has been tapped to serve as chief executive of the unnamed spin-off. Salvadori steps into the role with the mandate of navigating a fiercely competitive healthy nutrition market that has seen rapidly shifting consumer preferences. Analysts note that running a consumer-facing goods business presents inherently different supply chain and retail dynamics compared to the highly regulated sphere of medical technology. By removing internal competition for corporate capital, the spun-off nutrition titan will be free to focus entirely on staple brands like Glucerna and PediaSure.

Addressing Recent Challenges

While Abbott executives maintain the separation is about aligning investment profiles, industry observers are quick to point out the recent turbulent history of the nutrition division. Over the past few years, Abbott's infant formula business has weathered high-profile challenges, most notably the 2022 nationwide baby formula shortage triggered by a shutdown at its Sturgis, Michigan plant. The division continues to face thousands of pending lawsuits alleging that certain specialty formulas contributed to necrotizing enterocolitis (NEC) in premature infants. Wall Street remains eager for clarity on how this legacy legal liability will be apportioned between Abbott and the new entity once the split is finalized.

Wall Street Reaction

Despite the strategic logic behind the spin-off, financial markets initially reacted with tempered enthusiasm. Abbott's stock dipped nearly 2% in the wake of the announcement, reflecting broader anxieties after the company concurrently narrowed its full-year 2026 earnings forecast. In its third-quarter earnings report released alongside the spin-off news, Abbott revealed that while overall medical device sales slightly missed analyst expectations, the nutrition division itself posted a robust 5.1% increase, hauling in $2.26 billion.

Editorial Takeaway

Abbott’s decision to sever its nutrition business marks a pragmatic, albeit overdue, concession to the realities of modern conglomerate management. By unburdening its high-margin medical devices unit from the volatile, emotive, and heavily litigated consumer formula market, Abbott is signaling a return to its core scientific strengths. However, as the new standalone nutrition company prepares to brave the public markets on its own, it will need more than just brand recognition to survive; it must prove that it can innovate and rebuild consumer trust without the deep pockets of its former parent.